In our cohort, 20 patients developed breakthrough infections in the first six months after the last inoculation, with the majority not responders to the vaccine (12, 60%), but without any correlation with the IgM value, number of previous lines of therapy, neutropenia or active disease. This evidence concerns the gene CD40LG and neutropenia.